(Q43475358)

23 November 2017

title

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects (English)

1 reference

23 November 2017

1 reference

9

1 reference

23 November 2017

Ariela Benigni

10

0 references

Daniela Corna

series ordinal

2

object named as

Daniela Corna

1 reference

23 November 2017

1

Carla Zoja

1 reference

23 November 2017

8

Fabio Sangalli

1 reference

23 November 2017

4

Monica Locatelli

1 reference

23 November 2017

6

Flavio Gaspari

1 reference

23 November 2017

7

Fabiola Carrara

1 reference

23 November 2017

3

Valeria Nava

1 reference

23 November 2017

Mauro Abbate

5

1 reference

23 November 2017

publication date

7 November 2012

1 reference

American Journal of Physiology - Renal Physiology

23 November 2017

published in

1 reference

23 November 2017

volume

304

1 reference

23 November 2017

issue

6

1 reference

23 November 2017

page(s)

F808-19

1 reference

Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Effects of methimazole on the onset of type 2 diabetes in leptin receptor-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Dihydro-CDDO-trifluoroethyl amide (dh404), a novel Nrf2 activator, suppresses oxidative stress in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Bardoxolone methyl decreases megalin and activates nrf2 in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Clinical practice. Nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Bardoxolone Methyl, Chronic Kidney Disease, and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00376.2012

10.1152/AJPRENAL.00376.2012

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference